Pharmacokinetics of Gefitinib in a Patient with Non-Small Cell Lung Cancer Undergoing Continuous Ambulatory Peritoneal Dialysis

Publisher： Karger

E-ISSN： 1662-6575|8|1|78-82

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.8, Iss.1, 2015-02, pp. : 78-82

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-09 ,pp. : 464-466

Karger

Access to resources Recommend Favorite

Restoration of Gefitinib Efficacy Following Chemotherapy in a Patient with Metastatic Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 466-469

Karger

Access to resources Recommend Favorite

The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer

By Suzuki Takeshi   Mitsudomi Tetsuya   Hida Toyoaki  

Personalized Medicine, Vol. 1, Iss. 1, 2004-12 ,pp. : 27-34

Future Medicine

Access to resources Recommend Favorite

Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 509-513

Karger

Access to resources Recommend Favorite

A Novel Technique of the Retroperitoneoscopic Radical Nephrectomy for a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis to Preserve the Peritoneal Boundary

By  

Current Urology, Vol. 5, Iss. 2, 2011-07 ,pp. : 94-98

Karger

Access to resources Recommend Favorite